Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Cowen & Co. 39th Annual Health Care Conference 2019
30 slides from Senseonics's conference presentation, Mar 13, 2019
Slide 1: Live Life With Confidence and Ease
LIVE LIFE WITH CONFIDENCE AND EASE Cowen & Co. 39th Annual Health Care Conference 2019 11-13 March 2019
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are not purely historical regarding Senseonics’ or its management’s intentions, beliefs, expectations and strategies for the future. All forward-looking statements and reasons why results might differ included in t
Slide 3: High Growth Market
HIGH GROWTH MARKET CGM Fastest Growing Segment* $5 ~$2.2 B ~Ω 50% YOY ~$3.0 Revenue In Billions ($) $4 $3 $2.0 U.S. MARKET $1.7 $2 $1.2 $1 2016 2017 2018 2019 *Top 4 CGM company estimates based upon available publicly stated guidance, CGM Global Market Size historic performance, and external CGM mar
Slide 4: 27% Discontinue CGM Use Within 1 Year
27% DISCONTINUE CGM USE WITHIN 1 YEAR 71% 61% 41% 28% CGM NOT WORKING PROBLEMS WITH UNCOMFORTABLE CGM TOO BIG PROPERLY/ ADHESIVE/ TO WEAR ACCURATE ENOUGH INSERTION Type 1 Diabetes (T1D) Exchange Registry (2016) FOR INVESTORS ONLY | Cowen & Co. HC 2019 4
Slide 5: FOR INVESTORS ONLY | Cowen & Co. HC 2019
FOR INVESTORS ONLY | Cowen & Co. HC 2019 5
Slide 6: 36x a Year Patients Switch Out Sensor
36 x A YEAR PATIENTS HAVE TO SWITCH OUT THEIR SENSOR WITH OTHER CGM FOR INVESTORS ONLY | Cowen & Co. HC 2019 6
Slide 7: 36x vs 2-4x a Year Sensor Switches
36 x A YEAR 2-4 x A YEAR PATIENTS HAVE TO SWITCH PATIENTS HAVE TO SWITCH OUT THEIR SENSOR WITH OUT THEIR SENSOR WITH OTHER CGM EVERSENSE Labeled up to 90 days (US) and 180 days (Europe). FOR INVESTORS ONLY | Cowen & Co. HC 2019 7
Slide 8: The Eversense CGM System
THE EVERSENSE CGM ® THE ONLY CGM SYSTEM ¬¬ WITH FULLY IMPLANTABLE SENSOR ¬¬ SENSOR THAT LASTS UP TO 180 DAYS SENSOR SMART TRANSMITTER MOBILE APP ¬¬ WITH ON-BODY ++ Fully implanted ++ On-body vibe alerts ++ Real-time readings VIBE ALERTS ++ Small size ++ Removable/ every 5 mins ++ Up to 180 days rech
Slide 9: Eversense Clinical Evidence
EVERSENSE CLINICAL EVIDENCE The Eversense CGM System demonstrates strong performance across clinical studies. A1C Reduction Accuracy (MARD) Adherence Time in Target Hypoglycemic Overall A1C level Overall % Hours per day Overall % Detection 40-400 mg/dL 70-180 mg/dL Overall % PRECISE1 70 mg/dL 0.4% 2
Slide 10: Countries We're In
COUNTRIES NORWAY WE’RE IN DENMARK NETHERLANDS SWEDEN FINLAND BELGIUM UK GERMANY AUSTRIA POLAND SWITZERLAND CZECH REPUBLIC SPAIN USA ITALY SOUTH AFRICA 2018 for 2017 for 2016 for Eversense® CGM Eversense® XL CGM Eversense® CGM (90-Day System) (180-Day System) (90-Day System) FOR INVESTORS ONLY | Cowe
Slide 11: US Launch Acceleration: Aetna Coverage
US LAUNCH October 2018 ACCELERATION Advances AETNA Aetna covers approximately ANNOUNCES 22 million lives in the U.S., COVERAGE OF THE 1 adding to the growing body of payers processing claims EVERSENSE® CGM and paying for Eversense. SYSTEM FOR INVESTORS ONLY | Cowen & Co. HC 2019 11
Slide 12: US Launch Acceleration: FDA Expands Certification
US LAUNCH November 2018 ACCELERATION Advances Making Eversense CGM 90-day technology available to more diabetes patients. FDA EXPANDS EVERSENSE® CGM CERTIFICATION TO 2 Giving NPs and PAs another INCLUDE NURSE CGM option for their patients. PRACTITIONERS (NP) AND PHYSICIAN Allowing physicians to bett
Slide 13: US Launch Acceleration: MRI Contraindication Removed
US LAUNCH February 2019 ACCELERATION Advances Now, under most circumstances and on most MRI machines: FDA ANNOUNCES The Eversense Smart Sensor EVERSENSE IS NO LONGER 3 need not be removed before an MRI - reducing concerns CONTRA-INDICATED for patients and doctors alike. FOR MOST MRI’S Note: as with
Slide 14: US Launch Acceleration: Non-Adjunctive Indication
US LAUNCH Target Launch: Mid 2019 ACCELERATION Advances NON-ADJUNCTIVE Application to expand Eversense INDICATION indication as a therapeutic CGM; 4 replace fingerstick blood glucose measurement. Pending FDA Approval FOR INVESTORS ONLY | Cowen & Co. HC 2019 14
Slide 15: Eversense Patients by Previous CGM Used
16% 40% Libre U.S. Dexcom® EVERSENSE PATIENTS* 19% 24% Medtronic SMBG *% of Eversense users by previous CGM used. FOR INVESTORS ONLY | Cowen & Co. HC 2019 15
Slide 16: Eversense Patient Testimonials
90 DAYS OF CONTINUOUS MONITORING HAS changed my life. I’d tried other CGMs and never had success. THEY ALARMED INACCURATELY, AND THE INSERTION WAS DIFFICULT. Finally! I’m in range 90% OF THE TIME. having all the data… I get a report 1 day, 7 days, 30 days, 90 days. EVERSENSE PATIENT I feel safe slee
Slide 17: Eversense Patient Testimonials
THE 90-DAY WEAR TIME IS A LIFE-CHANGER ... I can focus on work…on my family…not my diabetes. BUT IT’S NOT JUST THE DATA IT GIVES ME … it’s the freedom it gives me. I can exercise, play with my kids…if the transmitter comes off, I just put it back … NO WAITING FOR IT TO WARM UP. GETTING THE SENSOR WA
Slide 18: Changing Reimbursement for Diabetes
CHANGING REIMBURSEMENT FOR DIABETES 60 MILLION LIVES 2018 TARGET 100 MILLION LIVES 2019 Coverage FOR INVESTORS ONLY | Cowen & Co. HC 2019 18
Slide 19: Changing Reimbursement for Diabetes
CHANGING REIMBURSEMENT FOR DIABETES 60 MILLION LIVES 2018 TARGET 100 MILLION LIVES 2019 Coverage DME PHARMACY CPT Coding FOR INVESTORS ONLY | Cowen & Co. HC 2019 19
Slide 20: Changing Reimbursement for Diabetes
CHANGING REIMBURSEMENT FOR DIABETES 60 MILLION LIVES 2018 TARGET 100 MILLION LIVES 2019 Coverage DME PHARMACY CPT Coding INDUSTRY STANDARDS Payment FOR INVESTORS ONLY | Cowen & Co. HC 2019 20
Slide 21: Changing Reimbursement for Diabetes
CHANGING REIMBURSEMENT FOR DIABETES 60 MILLION LIVES 2018 TARGET 100 MILLION LIVES 2019 Coverage DME PHARMACY CPT Coding INDUSTRY STANDARDS NEW CGM PARADIGM Payment FOR INVESTORS ONLY | Cowen & Co. HC 2019 21
Slide 22: Bridge Access Programs
CHANGING REIMBURSEMENT FOR DIABETES BRIDGE ACCESS PROGRAMS 60 MILLION LIVES 2018 TARGET 100 MILLION LIVES 2019 Coverage DME PHARMACY CPT Coding INDUSTRY STANDARDS NEW CGM PARADIGM Payment FOR INVESTORS ONLY | Cowen & Co. HC 2019 22
Slide 23: Bridge Access Programs
CHANGING REIMBURSEMENT FOR DIABETES “No Patient Left Behind” BRIDGE ACCESS PROGRAMS 60 MILLION LIVES 2018 TARGET 100 MILLION LIVES 2019 Coverage DME PHARMACY CPT Coding INDUSTRY STANDARDS NEW CGM PARADIGM Payment FOR INVESTORS ONLY | Cowen & Co. HC 2019 23
Slide 24: Partnerships and Alliances
PARTNERSHIPS AND ALLIANCES FOR INVESTORS ONLY | Cowen & Co. HC 2019 24
Slide 25: Europe Distributor Commercialization
EUROPE DISTRIBUTOR COMMERCIALIZATION Roche Diabetes Care +167% +266% Select EMEA, Asia Pac, LATAM markets Rubin Medical Scandinavia distributor 2017 2018 2017 2018 New Patients Sensor Insertions PharmaNova >700 >900 Finland distributor Eversense Trained Clinics Physicians FOR INVESTORS ONLY | Cowen
Slide 26: Europe Commercial Experience
EUROPE COMMERCIAL 10% 50% EXPERIENCE Traditional CGM New to CGM Most important features of the Eversense System: NEW PATIENTS • Long sensor life (Germany) • Predictive alerts • Readings on phone • On-body vibe alerts • Gentle adhesive 40% FGM FOR INVESTORS ONLY | Cowen & Co. HC 2019 26
Slide 27: Product Strategy
PRODUCT STRATEGY Extend Interoperability + Approval for Duration Decision Support Pediatrics Improve Lower Broaden Reduce Accuracy Cost Target Market Calibration FOR INVESTORS ONLY | Cowen & Co. HC 2019 27
Slide 28: Automated Insulin Delivery: Beta Bionics Program
AUTOMATED INSULIN DELIVERY BETA BIONICS PROGRAM Eversense / iLet Pump and Algorithm iLet™ Bionic Pancreas System with Eversense FOR INVESTORS ONLY | Cowen & Co. HC 2019 28
Slide 29: Eversense Pipeline (Future)
EVERSENSE PIPELINE (FUTURE) 365 DAY ON-DEMAND: TYPE 1 : SENSOR LIFE TYPE 2 GEMINI 1 ¬¬ 1x/week calibration 2 ¬¬ FGM ¬¬ Long-term wear w/ no transmitter 3 ¬¬ FGM +CGM ¬¬ Flash when desired ¬¬ CGM for peace of mind Same sensor technology. Expanded opportunities. FOR INVESTORS ONLY | Cowen & Co. HC 201
Slide 30: Thank You
| THANK YOU
Senseonics Holdings — Cowen & Co. 39th Annual Health Care Conference 2019 on 6ix